Research Analysts Set Expectations for SGMO FY2024 Earnings

Sangamo Therapeutics, Inc. (NASDAQ:SGMOFree Report) – Investment analysts at HC Wainwright cut their FY2024 earnings per share estimates for shares of Sangamo Therapeutics in a report issued on Thursday, November 14th. HC Wainwright analyst P. Trucchio now forecasts that the biopharmaceutical company will post earnings of ($0.43) per share for the year, down from their prior estimate of ($0.40). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Sangamo Therapeutics’ current full-year earnings is ($0.50) per share. HC Wainwright also issued estimates for Sangamo Therapeutics’ Q3 2025 earnings at ($0.04) EPS.

Sangamo Therapeutics (NASDAQ:SGMOGet Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.07. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The company had revenue of $49.41 million for the quarter, compared to analyst estimates of $26.55 million. During the same quarter in the previous year, the company earned ($0.34) EPS.

A number of other equities research analysts also recently issued reports on the stock. Barclays lifted their price target on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the company an “overweight” rating in a research report on Thursday. StockNews.com upgraded Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday.

Get Our Latest Stock Report on SGMO

Sangamo Therapeutics Trading Down 4.7 %

SGMO stock opened at $2.05 on Monday. The firm has a 50 day moving average of $1.33 and a 200-day moving average of $0.87. Sangamo Therapeutics has a 12-month low of $0.30 and a 12-month high of $3.18. The company has a market cap of $427.73 million, a price-to-earnings ratio of -2.73 and a beta of 1.10.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Acadian Asset Management LLC raised its position in shares of Sangamo Therapeutics by 4.0% during the 1st quarter. Acadian Asset Management LLC now owns 4,943,260 shares of the biopharmaceutical company’s stock worth $3,311,000 after purchasing an additional 192,385 shares during the last quarter. Renaissance Technologies LLC grew its stake in Sangamo Therapeutics by 58.8% in the 2nd quarter. Renaissance Technologies LLC now owns 4,126,577 shares of the biopharmaceutical company’s stock worth $1,479,000 after acquiring an additional 1,528,600 shares during the period. Geode Capital Management LLC grew its stake in Sangamo Therapeutics by 14.6% in the 3rd quarter. Geode Capital Management LLC now owns 2,138,309 shares of the biopharmaceutical company’s stock worth $1,853,000 after acquiring an additional 272,123 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of Sangamo Therapeutics by 5.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,103,326 shares of the biopharmaceutical company’s stock valued at $956,000 after buying an additional 57,125 shares during the period. Finally, State Street Corp grew its stake in shares of Sangamo Therapeutics by 28.0% during the 3rd quarter. State Street Corp now owns 664,621 shares of the biopharmaceutical company’s stock valued at $576,000 after buying an additional 145,400 shares during the period. 56.93% of the stock is currently owned by institutional investors and hedge funds.

Sangamo Therapeutics Company Profile

(Get Free Report)

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.

Featured Articles

Earnings History and Estimates for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.